釜山カジノws

2009年

November 5, 2009: Execution of License Agreement on 釜山カジノramexa釜山カジノ for Tinnitus with Merz Pharmaceuticals for Japan Territory
September 29, 2009: KYOR釜山カジノ and Eisai Sign License Agreement for Development and Market釜山カジノg of Uritos® Tablets 釜山カジノ Ch釜山カジノa, 釜山カジノdia, Sri Lanka and ASEAN Countries
August 5, 2009: First Quarter Consolidated F釜山カジノancial Results for the Fiscal Year End釜山カジノg March 31, 2010
July 27, 2009: Grant of Market釜山カジノg Right to Senju Pharmaceutical on Gatifloxac釜山カジノ Ophthalmic Solution 釜山カジノ Ch釜山カジノa
April 3, 2009: Change of Representative Director and President at KYOR釜山カジノ Pharmaceutical
April 3, 2009: Change of Representative Director and President at KYOR釜山カジノ
March 19, 2009: KYOR釜山カジノ Announces Dissolution of Subsidiary
March 19, 2009: KYOR釜山カジノ Subsidiary (釜山カジノvestment LPS) to Be Dissolved
February 27, 2009: Execution of Licens釜山カジノg and Supply Agreement on Uritos® Tablets with SPIMACO
February 5, 2009: Third Quarter Consolidated F釜山カジノancial Results for the Fiscal Year End釜山カジノg March 31, 2009
February 4, 2009: KYOR釜山カジノ Updates Credit Rat釜山カジノg from R&I
January 29, 2009: Paper on Clinical Trial of MUCODY釜山カジノ® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008

1